Collaboration Will Evaluate Charge-altering Releasable Transporter System for mRNA Delivery to T Cells Research Will Be Led by Stanford Researchers Robert Waymouth, Ph.D., Paul Wender , Ph.D. and Ronald Levy , M.D. SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Allogene

SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Morgan

ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Advances with Five Clinical Trial Sites Open Investigational New Drug (IND) Application Cleared by the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients

Dr. Amado’s Addition to the Senior Leadership Team Reunites Him with Former Colleagues in the Pursuit of Novel Immunotherapies SOUTH SAN FRANCISCO, Calif , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development

Conference Call and Webcast Scheduled for 5:30 AM PT / 8:30 AM ET   SOUTH SAN FRANCISCO, Calif. , July 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer,

ALLO-715 Utilizes Gene-Editing of TRAC and CD52 Loci to Enable Allogeneic CAR T Therapy ALLO-715 will be Evaluated in Combination with ALLO-647, Allogene’s Proprietary anti-CD52 Antibody as Part of the Lymphodepletion Regimen  Allogene Plans to Initiate the UNIVERSAL Study for ALLO-715 in

SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at three investor

Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Investigational New Drug (IND) Application Submitted to the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients with Relapsed/Refractory Multiple

Newly Appointed Members Include Robert Abraham, Ph.D., Malcolm K. Brenner, M.D., Ph.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D. SOUTH SAN FRANCISCO, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today